IBI302
Neovascular age‑related macular degeneration
Phase 3Active
Key Facts
About AP Biosciences
AP Biosciences leverages a bispecific antibody platform to advance oncology and ophthalmology candidates through late‑stage clinical trials.
View full company profileTherapeutic Areas
Other Neovascular age‑related macular degeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| Ranibizumab Biosimilar | Biomm | Approved |
| EY-002 | EyeYon Medical | Phase 1 |